Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Viswanathan
Avinash
A
Pillot
Giancarlo
G
Govindan
Ramaswamy
R
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D011799:Quinazolines; C015482:protein kinase modulator; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib